Accidental Information Literacy Instruction: The Work a Link Landing Page Can Do

This article reports on a surprise finding from a larger, long-term study that explores ways to provide effective information literacy instruction (ILI) in asynchronous, online-only courses. The finding occurred during a term in which students participating in the study received no formal ILI. However, these students did not turn to the web at large when doing independent research as some literature might predict. Instead, analysis of their final research project bibliographies suggests students modeled the search scopes of select prior assignments from that same course. This finding has potential to inform parameters for adapting pedagogy for asynchronous, online-only instruction as well as ways librarians and teaching faculty collaborate to incorporate ILI into curricula, particularly in online contexts

E‐Book Tune‐Up: Maintaining, Sustaining, and Expanding Your Demand‐Driven E‐Book Program

Just like a car, an e‐book program needs continuous maintenance in order to run smoothly. What can we do to structure our e‐book collections to better meet institutional need? Many factors come into play in building a successful demand‐driven acquisition (DDA) program. Student preferences, actual use, collection development, and faculty/staff education and support are all important aspects of maintaining and sustaining a DDA program. This paper describes how the Furman University Library in South Carolina and the Metropolitan State University Library (Metro State) in Minnesota assessed and fine‐tuned their respective DDA programs, and the results of these changes

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

International audienceBACKGROUND Nusinersen is an antisense oligonucleotide drug that modulates pre-messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA). METHODS We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of nusinersen in 126 children with SMA who had symptom onset after 6 months of age. The children were randomly assigned, in a 2: 1 ratio, to undergo intrathecal administration of nusinersen at a dose of 12 mg (nusinersen group) or a sham procedure (control group) on days 1, 29, 85, and 274. The primary end point was the least-squares mean change from baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score at 15 months of treatment; HFMSE scores range from 0 to 66, with higher scores indicating better motor function. Secondary end points included the percentage of children with a clinically meaningful increase from baseline in the HFMSE score (>= 3 points), an outcome that indicates improvement in at least two motor skills. RESULTS In the prespecified interim analysis, there was a least-squares mean increase from baseline to month 15 in the HFMSE score in the nusinersen group (by 4.0 points) and a least-squares mean decrease in the control group (by -1.9 points), with a significant between-group difference favoring nusinersen (least-squares mean difference in change, 5.9 points; 95% confidence interval, 3.7 to 8.1; P< 0.001). This result prompted early termination of the trial. Results of the final analysis were consistent with results of the interim analysis. In the final analysis, 57% of the children in the nusinersen group as compared with 26% in the control group had an increase from baseline to month 15 in the HFMSE score of at least 3 points (P< 0.001), and the overall incidence of adverse events was similar in the nusinersen group and the control group (93% and 100%, respectively). CONCLUSIONS Among children with later-onset SMA, those who received nusinersen had significant and clinically meaningful improvement in motor function as compared with those in the control group. (Funded by Biogen and Ionis Pharmaceuticals; CHERISH ClinicalTrials. gov number, NCT02292537.